Loading...

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing–remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patien...

Full description

Saved in:
Bibliographic Details
Published in:CNS Drugs
Main Authors: Chan, Andrew, de Seze, Jérôme, Comabella, Manuel
Format: Artigo
Language:Inglês
Published: Springer International Publishing 2016
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4733135/
https://ncbi.nlm.nih.gov/pubmed/26758290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-015-0299-y
Tags: Add Tag
No Tags, Be the first to tag this record!